Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2022 | The reproducibility of decision-making at a MTB for treatment strategies of stage IIIA NSCLC

Nicolas Girard, MD, PhD, Institut Curie, Paris, France, talks on an investigation into the execution and reproducibility of the decision making involved at a Multidisciplinary Tumor Board (MTB) for surgical resection with neoadjuvant or adjuvant therapy versus chemoradiation for patients with stage IIIA non-small cell lung cancer (NSCLC). Decision making is based on the resectability of the tumor, which is not well defined for this patient population. Histology, tumor size and location and lymph node involvement were characterized for the decision making process. Overall, there was a 70% consistency rate on whether to opt for surgery between the initial MTB decision and blinded re-discussion. This interview took place during the virtual European Lung Cancer Congress 2022.